Thermodox, a liver cancer drug of celsion, a partner of Haizheng pharmaceutical, has not reached the end of clinical study

Haizheng Pharmaceutical Co., Ltd announced on the evening of January 31 that it would terminate its cooperation with the company on the product, because the company's partner, U.S celsion company, announced that thermodox ® combined with radiofrequency ablation in the phase III clinical research (heat research) of primary liver cancer did not reach the main clinical research end point It is reported that according to the results of thermodox phase III clinical study released by celsion company at 8:00 p.m on January 31, thermodox combined with radiofrequency ablation in the phase III clinical study (heat study) of primary liver cancer did not reach the main clinical study end point Compared with radiofrequency ablation alone, thermodox and radiofrequency ablation improved the disease-free progression of patients with mid-term liver cancer by 33%, P = 0.05 ThermoDox was well tolerated in the study, with no serious adverse reactions In view of this, the company said that it would terminate its intention to develop and sell thermodox ® in mainland China, Hong Kong and Macao, and would not pay any follow-up fees The company said that in the future, it will further decide whether to carry out clinical research, registration and market development of thermodox ® in China based on the results of subgroup analysis, especially the results of Chinese patient subgroup analysis On January 23, 2013, Haizheng pharmaceutical said that it had signed an intentional agreement with celsion for the development and sale of thermodox, the latter's patented product, in mainland China, Hong Kong and Macao Nevertheless, the company said that the $5 million previously paid by the company to celsion for liposome technology development would not be changed by the results of thermodox ® phase III clinical research The company will continue to be committed to the development of new liposome technology, and improve the company's international level and industrialization capacity in liposome process preparation On January 31, Haizheng pharmaceutical said 17.23 yuan, down 1.26%.